Although our sample size is small, these findings lay the foundation for future biomarker studies to test whether FLT1 activation in pre-treatment biopsies can be used to stratify breast cancer patients at high risk for rapidly acquiring resistance to PARPi. Here, FLT1 is linked to breast carcinoma.